IFNA2 and cryohydrocytosis: About 50% of CHC patients infected with HCV genotype 1 could achieve sustained virological response (SVR) under the therapy of pegylated IFN-α and ribavirin (PEG IFN-α/RBV), while the rate may increase to 70–90% for those infected with genotype 2/34.